Ocugen Launches Phase 2/3 Clinical Trial for Stargardt Disease Gene-Modifier Therapy
July 22, 2025
July 22, 2025
COLUMBIA, Maryland, July 22 -- The Foundation Fighting Blindness issued the following news:
* * *
Ocugen Launches Phase 2/3 Clinical Trial for Stargardt Disease Gene-Modifier Therapy
The therapy delivers copies of the RORA gene to address multiple disease pathways.
*
The biotechnology company Ocugen has dosed the first patient in its Phase 2/3 GARDian3 clinical trial for OCU410ST, an emerging gene-modifier therapy for people with S . . .
* * *
Ocugen Launches Phase 2/3 Clinical Trial for Stargardt Disease Gene-Modifier Therapy
The therapy delivers copies of the RORA gene to address multiple disease pathways.
*
The biotechnology company Ocugen has dosed the first patient in its Phase 2/3 GARDian3 clinical trial for OCU410ST, an emerging gene-modifier therapy for people with S . . .